Dive into the Biopharma Space

Seattle continues to make waves in the life sciences arena, blending the city’s deep research heritage with a new generation of biotech innovation. From next-generation antibody-drug conjugates to advanced RNA vaccines, the Emerald City is home to companies pushing the boundaries of how we diagnose, treat, and understand disease. Here are 10 companies to watch in 2025 , each driving fresh breakthroughs through clinical success, funding momentum, or technological innovation.

Southern California has long been known for its beaches and biotech, and nowhere is the region’s innovation more evident than in its antibody ecosystem . From San Diego’s wet labs  to Pasadena’s protein engineers , the area has become a proving ground for companies blending creativity, capital, and clinical progress. At BiopharmIQ, we’ve tracked more than a hundred SoCal bio/pharma's developing antibody-based drugs, and we’ve handpicked 10 companies to watch in 2025 , chosen

" Private bio/pharma funding activity strengthened in September, reaching its highest level since early 2025 and reflecting a gradual re-acceleration in deal flow. " September 2025 marks the end of the third quarter with a significant uptick in deal activity , even though total dollars raised remain below early-year highs. The market continues to favor non-dilutive funding and smaller financings, with grants leading by deal count  and early-stage rounds bouncing back  from th

At BiopharmIQ , we’ve mapped over 280 biotech and pharma companies in Texas, tracking the rapid evolution of one of the most dynamic innovation hubs in the U.S. What once was a regional life sciences cluster is now a full-fledged ecosystem, where emerging bio/pharmas, mid-sized innovators, and major pharmaceutical players converge. This year’s landscape highlights clinical-stage activity, late preclinical acceleration, and significant capital infusions across therapeutic are

At BiopharmIQ , we’ve mapped 377 companies in the global AAV landscape . This work gave us a broad view of the ecosystem, from vector engineering innovators to clinical-stage pioneers and emerging players in new geographies. While big pharma has made major moves into AAV, this list focuses on bio/pharmas and mid-sized innovators  that stand out for their technology novelty, recent funding, promising clinical results, or regulatory momentum . Do you have them on your radar? 👁

"Private bio/pharma funding rebounded in value in August, though deal counts remain subdued." August 2025 marked the seventh consecutive...

Radiopharmaceuticals are rapidly gaining attention across the biopharma industry, combining targeted delivery with therapeutic...

Cell therapy continues to be one of the most dynamic segments of biotech and pharma financing in 2025. From oncology to neurology,...

2025 Bio/Pharma Funding Trends: July’s Update

In Q1 2025, 26 new and emerging bio/pharma companies were identified, with the majority based in the U.S.—California and Massachusetts leading the count. Most of these companies focus on therapeutics, signaling strong investor interest. Verdiva Bio topped funding with $411M, followed by Kardigan and Windward Bio. Explore geographic trends, sector focus, and top-funded startups in our latest biopharmIQ report.

Gene editing has emerged as one of the most transformative technologies in biotech and pharma, with applications spanning therapeutics,...

The latest wave of new and emerging biologic companies in 2024 highlights a continued diversity of technology areas with a strong focus...

This annual report analyzes our biopharmIQ data on new/emerging bio/pharma companies for 2024 to provide insights into the geographic and...

We identified two (2) new or newly emerging biotech companies for December 2024. To find these new/emerging bio/pharma companies, every...

We’ve identified seven (7) new or newly emerging bio/pharma companies for November 2024. To detect these new/emerging bio/pharma ...

There is a lot that has been published about the possible impact of AI on healthcare and the development of new therapeutics. In fact,...

We analyzed biotech funding data on our online biopharmIQ platform  to identify companies who had late-stage* biotech funding events...

A valuable signal (i.e. hot lead) for vendors is when a potential customer closes a funding round. We identify these funding events and...

New cell & gene therapy (CGT) companies continue to emerge in 2024. To detect these new/emerging CGT companies, every workday, our team...

We analyzed biotech funding data on our online biopharmIQ platform  to identify companies who had early-stage (Angel/Pre-Seed, Seed,...